ArticleFrontiers in immunology2026
Risk factors analysis and validation of early treatment non-response in children with primary ITP: a multicenter retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify factors associated with early non-response to first-line treatment in children with primary immune thrombocytopenia (ITP), and to develop and externally validate a prediction model. Methods: This multicenter retrospective cohort study included 335 children with newly diagnosed primary ITP as the derivation cohort, including 255 responders and 80 non-responders. Clinical data obtained after admission were collected. Candidate variables were screened using correlation analysis and least absolute shrinkage and selection operator (LASSO) regression, followed by multivariable logistic regression to identify factors associated with early treatment non-response. Model discrimination was evaluated using the area under the receiver operating characteristic curve (AUC). An independent external validation cohort of 78 children was additionally included to assess model discrimination. Results: Among the 335 children, 255 (76.1%) achieved a treatment response within 14 days after first-line therapy, whereas 80 (23.9%) did not. Multivariable analysis showed that older age (OR = 1.769, 95% CI: 1.629-1.920, P < 0.001), higher platelet-to-lymphocyte ratio (PLR) (OR = 1.622, 95% CI: 1.112-2.367, P = 0.012), and antinuclear antibody (ANA) positivity (OR = 3.142, 95% CI: 1.626-6.071, P < 0.001) were independently associated with early treatment non-response. The combined model incorporating age, PLR, and ANA achieved an AUC of 0.831 (95% CI: 0.778-0.885) in the derivation cohort and 0.718 (95% CI: 0.591-0.845) in the independent external validation cohort. Calibration was acceptable in both cohorts, with Hosmer-Lemeshow P values of 0.609 and 0.220 and Brier scores of 0.129 and 0.137, respectively. Conclusion: Older age, higher PLR, and ANA positivity were independently associated with early non-response to first-line treatment within 14 days in children with newly diagnosed primary ITP. These findings may help identify children at high risk of treatment non-response and support individualized monitoring and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.